-+ 0.00%
-+ 0.00%
-+ 0.00%

Barclays Downgrades Regenxbio to Equal-Weight, Maintains Price Target to $12

Benzinga·08/07/2026 10:36:29
Listen to the news
Barclays analyst Eliana Merle downgrades Regenxbio (NASDAQ:RGNX) from Overweight to Equal-Weight and maintains the price target from $12 to $12.